Id: | acc2020 |
Group: | 2sens |
Protein: | AMPK |
Gene Symbol: | PRKAA1 |
Protein Id: | Q13131 |
Protein Name: | AAPK1_HUMAN |
PTM: | phosphorylation |
Site: | Thr183 |
Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
Disease Category: | Cancer |
Disease: | Breast Cancer |
Disease Subtype: | |
Disease Cellline: | MCF7 |
Disease Info: | |
Drug: | docosahexaenoic acid(DHA) |
Drug Info: | "Docosahexaenoic acid (DHA) is an omega-3 fatty acid used in dietary supplements to support brain, eye, and cardiovascular health, and as a component of prescription omega-3 acid ethyl ester formulations for managing severe hypertriglyceridemia." |
Effect: | modulate |
Effect Info: | DHA promotes the phosphorylation of AMPK and inhibits tumors. |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 24025358 |
Sentence Index: | 24025358_4-5 |
Sentence: | "Here, we show that omega3PUFA, docosahexaenoic acid (DHA) enhanced the tumor suppressor function of LKB1. We observed that when LKB1 expressing cells are treated with DHA, there is an increase in LKB1 activity leading to phosphorylation of AMPK and inhibition of mTOR signaling." |
Sequence & Structure:
MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACPRKAA1-Thr183 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | -0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 183 | D | Colon cancer/carcinoma | Phosphorylation | 25679763 |
T | 183 | U | Breast cancer | Phosphorylation | 30413706 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.